默沙东架构调整!成熟产品进集采后,MNC借力创新运营模式

医药经济报
Yesterday

整合资源捍卫市场份额据悉,默沙东此番新设的企业家事业部前身是成立于2015年7月的糖尿病事业部(DBU)。彼时,默沙东将糖尿病视为四大重点治疗领域之一,核心产品包括西格列汀和西格列汀二甲双胍等。有数据显示,默沙东的西格列汀及其西格列汀二甲双胍在2022年的全球销售收入高达45.13亿美元。但受到竞品影响,2023年,两款药物合计销售额已减少至33.66亿美元。不过在‌默沙东2024年的中国药品业务...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10